Triangle2141-V11 (NCT07818018)
2141-V11 trial for Advanced Esophageal, Gastric or GEJ Cancer (NCT07818018). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced esophageal, stomach, or gastroesophageal junction cancer who are already on first line treatment.
The idea: inject 2141-V11 directly into a tumor while patients continue standard immunotherapy, with or without 5-FU chemotherapy. 2141-V11 is an antibody that switches on CD40, a receptor that can help start an immune response.
The study looks first at safety.
This phase 1 and 2 study plans 30 patients. At Memorial Sloan Kettering Cancer Center in New York, Samuel Cytryn leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.